EMEA-001813-PIP01-15
Key facts
| Active substance |
Recombinant humanized anti-MMP9 monoclonal antibody IgG4 (GS-5745)
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0146/2016
|
| PIP number |
EMEA-001813-PIP01-15
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|